Mirum Pharmaceuticals Inc
NASDAQ:MIRM

Watchlist Manager
Mirum Pharmaceuticals Inc Logo
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Watchlist
Price: 41.73 USD 0.53% Market Closed
Market Cap: 2B USD
Have any thoughts about
Mirum Pharmaceuticals Inc?
Write Note

Mirum Pharmaceuticals Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mirum Pharmaceuticals Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Short-Term Investments
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Short-Term Investments
$28m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Short-Term Investments
$1.3B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Short-Term Investments
$7.8B
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
35%
No Stocks Found

Mirum Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, Mirum Pharmaceuticals Inc. has carved a niche for itself by specializing in rare liver diseases, a domain that requires both precision and dedication. Founded with a visionary goal, the company primarily focuses on developing treatments that address serious unmet needs within this sphere. At the heart of its operations is the development of maralixibat, a promising drug targeting progressive familial intrahepatic cholestasis and Alagille syndrome, which are both debilitating liver conditions affecting young patients. By addressing these niche markets, Mirum positions itself uniquely, translating complex science into tangible health outcomes. The company makes its money by navigating the rigorous path of drug development, from clinical trials to receiving regulatory approvals, ultimately transforming these therapies into marketable products. Mirum's business model is interlaced with the high stakes world of pharmaceuticals, where innovation meets exhaustive research and development. Revenue generation is contingent upon both the successful commercialization of its drug pipeline and strategic partnerships, which bolster their market reach and resource agility. By engaging closely with healthcare professionals and leveraging compassionate use and expanded access programs, they not only facilitate early adoption but also fuel the momentum needed for market penetration. Moreover, Mirum's commitment to education and engagement strategies fosters a robust ecosystem that underscores the importance of treating rare diseases. This way, the company not only sells its therapeutics but also creates enduring relationships within the medical community, significantly anchoring its financial and operational standing.

MIRM Intrinsic Value
56.01 USD
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Mirum Pharmaceuticals Inc's Short-Term Investments?
Short-Term Investments
0 USD

Based on the financial report for Dec 31, 2023, Mirum Pharmaceuticals Inc's Short-Term Investments amounts to 0 USD.

Back to Top